Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia

Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious Staphylococcus aureus infections. Sixty patients with documented S. aureus bacteremia (SAB) were randomized and receiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Weems, J. John, Steinberg, James P., Filler, Scott, Baddley, John W., Corey, G. Ralph, Sampathkumar, Priya, Winston, Lisa, John, Joseph F., Kubin, Christine J., Talwani, Rohit, Moore, Thomas, Patti, Joseph M., Hetherington, Seth, Texter, Michele, Wenzel, Eric, Kelley, Violet A., Fowler, Vance G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2006
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1538656/
https://ncbi.nlm.nih.gov/pubmed/16870768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00096-06
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados